Volume 2.41 | Oct 28

Mammary Cell News 2.41 October 28, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Repression of Mammary Stem/Progenitor Cells by P53 is Mediated by Notch and Separable from Apoptotic Activity  ShareThis
The results demonstrate that basal levels of p53 restrict mammary stem/progenitor cells through Notch and that the Notch pathway is a therapeutic target to prevent expansion of this vulnerable pool of cells. [Stem Cells]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies


Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]

Follow us on Twitter!  @MammaryCell


Scientists Show TAp63 Suppresses Cancer Metastasis
Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Nature]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-Modulation of the Estrogen Receptor in HER2-Positive Breast Cancers
The results reveal a mechanism of estrogen receptor regulation mediated by human epidermal growth factor receptor 2, which suggests a new strategy to improve responses to endocrine therapy in breast cancer. [Cancer Res]

mTOR Complex Component Rictor Interacts with PKCZeta and Regulates Cancer Cell Metastasis
Here, researchers report that the rapamycin-insensitive mTORC2 component protein Rictor is a critical mediator of metastasis in breast cancer cells. [ Cancer Res]

Down-Regulation of the Oncogene Cyclin D1 Increases Migratory Capacity in Breast Cancer and Is Linked to Unfavorable Prognostic Features
The oncogene cyclin D1 is highly expressed in many breast cancers and, despite its proliferation-activating properties, it has been linked to a less malignant phenotype. To clarify this observation, researchers focused on two key components of malignant behavior, migration and proliferation, and observed that quiescent G0/G1 cells display an increased migratory capacity compared to cycling cells. [Am J Pathol]

Adipocyte Derived Paracrine Mediators of Mammary Ductal Morphogenesis Controlled by Retinoic Acid Receptors
Researchers generated a transgenic-mouse model expressing a dominant negative-RARalpha, (RARalphaG303E) under adipocytes-specific promoter to explore the paracrine role of adipocyte retinoic acid receptors (RARs) in mammary morphogenesis. [Dev Biol]

RB-Pathway Disruption in Breast Cancer: Differential Association with Disease Subtypes, Disease-Specific Prognosis and Therapeutic Response
Researchers investigated RB pathway deregulation in the context of both ER-positive and ER-negative disease using combined microarray datasets encompassing over 900 breast cancer patient samples. [Cell Cycle]

Expression of ctBP Family Protein Isoforms in Breast Cancer and Their Role in Chemoresistance
The studies support recent evidence that CtBP family proteins represent potential targets for therapeutic strategies for the treatment of cancer in general, and breast cancer in particular. [Biol Cell]

Spontaneously Immortalised Bovine Mammary Epithelial Cells Exhibit a Distinct Gene Expression Pattern from the Breast Cancer Cells
Here, researchers report the establishment of a spontaneously immortalised bovine mammary epithelial cell line (BME65Cs) and the changes in gene expression associated with BME65Cs cells. [BMC Cell Biol]


Long-Term Survival Among Patients With Hodgkin’s Lymphoma Who Developed Breast Cancer: A Population-Based Study
Women with Hodgkin’s lymphoma may survive a subsequent diagnosis of breast cancer, only to experience significant excesses of death from other primary cancers and cardiac disease. [J Clin Oncol]

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
The purpose of this study was to determine the recommended dose of everolimus, a mammalian target of rapamycin inhibitor, combined with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer pretreated with trastuzumab. [J Clin Oncol]

Increased NOS2 Predicts Poor Survival in Estrogen Receptor-Negative Breast Cancer Patients
To investigate whether nitric oxide synthase (NOS2) levels influence survival of breast cancer patients, researchers examined NOS2 expression and its association with tumor markers and survival in 248 breast tumors. [J Clin Invest]

Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects
This is the first study demonstrating that single oral doses of endoxifen are safe and well tolerated and have sufficient bioavailability to reach systemically effective levels in human subjects. [Clin Pharmacol Ther]

A Protein Microarray Signature of Autoantibody Biomarkers for the Early Detection of Breast Cancer
Cancer patients spontaneously generate autoantibodies (AAb) to tumor-derived proteins. To detect AAb, researchers have probed novel high-density custom protein microarrays (NAPPA) expressing 4,988 candidate tumor antigens with sera from patients with early stage breast cancer, and bound IgG was measured. [J Proteome Res]


Unique Database of Cancer – Designed to Personalize Treatment – Is Launched
Georgetown Lombardi Comprehensive Cancer Center announces the launch of the Georgetown Database of Cancer or G-DOC. Under development for two years, G-DOC is a repository for biological information that is normally only available in scattered information libraries and tissue banks, if at all. [Georgetown University Medical Center Press Release]

Myriad and Abbott Enter Into Cooperative Agreement
Myriad Genetics, Inc. announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer. [Myriad Genetics, Inc. Press Release]

BioSante Pharmaceuticals Reports Positive LibiGel(R) Data Monitoring Committee Recommendation
BioSante Pharmaceuticals, Inc. announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). [BioSante Pharmaceuticals, Inc. Press Release]


NIH Recovery Act Awards Enable Crucial Health Research Technologies
Thanks to the Recovery Act, more health scientists now will have access to state-of-the-art devices, the National Institutes of Health announced. Through its National Center for Research Resources, NIH has awarded $300 million in shared instrumentation grants.  [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26362) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26363) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26317) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26497) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26499) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26028) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26702) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meetings (FR Doc. 2010-26706) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26390) [National Institutes of Health, United States]

Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-26036) [National Institutes of Health, United States]

EVENTS (Listed by Date)

Queen Mary University of London: 5th UK Cancer Stem Cell Symposium
November 2, 2010
London, United Kingdom

National Cancer Research Institute (NCRI) Conference 2010
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

NEW Third Annual Research Experience of Stem Cells in European Society (RESCUES) Conference
November 8-9, 2010
Oxford, United Kingdom

The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms
November 15-18, 2010
Nara, Japan

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

American Association for Cancer Research (AACR) 33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

28th Annual Miami Breast Cancer Conference
March 9-12, 2011
Miami, United States

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

NEW United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us